Genmab released its Q2 18 results in which the top-line was in line with our estimates while profitability exceeded expectations. Total revenue came in at DKK509.6m (vs. Q2 17: DKK773.3m, which benefited from higher milestone income) with royalties from Darzalex being the largest contributor. Net sales for the multiple myeloma/MM drug reached $511m (+18.3% qoq), resulting in royalties of DKK385m from its collaboration partner, Janssen. Reimbursement income of DKK47m (from Seattle Genetics and
16 Aug 2018
Decent results; Darzalex-Revlimid front-line approval awaited in the US
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Decent results; Darzalex-Revlimid front-line approval awaited in the US
Genmab A/S (GMAB:WBO) | 0 0 1.3% | Mkt Cap: 66,508m
- Published:
16 Aug 2018 -
Author:
Sumit Sayal -
Pages:
3
Genmab released its Q2 18 results in which the top-line was in line with our estimates while profitability exceeded expectations. Total revenue came in at DKK509.6m (vs. Q2 17: DKK773.3m, which benefited from higher milestone income) with royalties from Darzalex being the largest contributor. Net sales for the multiple myeloma/MM drug reached $511m (+18.3% qoq), resulting in royalties of DKK385m from its collaboration partner, Janssen. Reimbursement income of DKK47m (from Seattle Genetics and